/ /

Leah Lawrence
Biomarkers predict metastasis, biochemical recurrence
Clinicians may soon be able to improve the risk stratification of men with prostate cancer with the help of a genomic classifier or a biopsy-based reverse transcription polymerase chain reaction assay, according to the results of two studies presented at the Genitourinary Cancers Symposium in Orlando, FL.
Novel assay may help identify prostate Bx candidates
A simple blood test that measures PSA structure rather than concentration may be more accurate than PSA in identifying men who need a prostate biopsy, according to the results of a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Single-fraction HDR BT feasible for localized PCa
A definitive radiotherapy dose for localized prostate cancer can be safely administered using high-dose rate brachytherapy as a single outpatient procedure.
Mental health conditions contribute to PCa-related costs
Mood and adjustment disorders were strong predictors of the annual number of outpatient visits, hospital admissions, and number of days in the hospital for patients with prostate and breast cancer, according to a recent study.
Abdominal obesity linked to risk of type 2 diabetes
A genetic predisposition to having increased abdominal fat increased risk for diabetes and heart disease, according to a new study.
Diabetes responsible for more U.S. deaths than previously thought
Previous estimates based on cause of death on death certificates underestimated the problem.
PD-1 inhibitor benefit possible even after discontinuation
Persistent clinical benefit was seen among a small group of patients with metastatic renal cell carcinoma who had to discontinue therapy with the PD-1 inhibitor nivolumab (Opdivo) because of immune-related adverse events, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Antibiotics may negatively impact immunotherapy outcomes
Administration of broad-spectrum antibiotics in patients with metastatic renal cell carcinoma (RCC) undergoing treatment with immune checkpoint inhibitors may have a negative effect on the efficacy of the immunotherapy drugs, according to the results of a recent retrospective analysis.
High-deductible plan switch shows little effect on diabetes patients
New study indicates vulnerable subgroups of diabetes patients did experience adverse outcomes due to change in health insurance coverage.
CMS defines certain continuous glucose monitors as DME
New definition opens the door to full Medicare coverage for CGMs.